Thank you to all the patients, families, caregivers, and the Immune Deficiency Foundation community for visiting us at the 2024 Primary Immunodeficiency (PI) Reel Talk conference and sharing your stories. We heard loud and clear about the urgent need for early, accurate diagnosis and targeted treatments. Your stories inspire and motivate us to continue our work at X4 Pharmaceuticals in bringing innovative treatments to the PI community. We look forward to seeing you again at upcoming walks and next year’s conference. #2024PIConference
X4 Pharmaceuticals’ Post
More Relevant Posts
-
Have you checked out our medical information website? Explore our resources in oncology, including a convenient live chat function for your medical information questions during business hours. #oncology #medicalinformation #livechat #Eisai
To view or add a comment, sign in
-
There are over 10,000 rare diseases impacting small patient populations, but 95% of these lack any FDA-approved treatment, says the National Organization for Rare Disorders. For patients and caregivers navigating the complex diagnosis, treatment and care landscape, self-organized communities can be a lifeline. Our experts at Avalere Health investigated how these groups can be best supported and when biopharmaceutical companies should partner – and should step back. Download the whitepaper now: https://bit.ly/3SRVGDA #AvalereHealth #RareDisease #PatientCommunities
Avalere Health | Putting the patient first: Moving from patient communities to patient co-creation in rare disease
avalerehealth.com
To view or add a comment, sign in
-
There are over 10,000 rare diseases impacting small patient populations, but 95% of these lack any FDA-approved treatment, says the National Organization for Rare Disorders. For patients and caregivers navigating the complex diagnosis, treatment and care landscape, self-organized communities can be a lifeline. Our experts at Avalere Health investigated how these groups can be best supported and when biopharmaceutical companies should partner – and should step back. Download the whitepaper now: https://bit.ly/3SRVGDA #AvalereHealth #RareDisease #PatientCommunities
Avalere Health | Putting the patient first: Moving from patient communities to patient co-creation in rare disease
avalerehealth.com
To view or add a comment, sign in
-
There are over 10,000 rare diseases impacting small patient populations, but 95% of these lack any FDA-approved treatment, says the National Organization for Rare Disorders. For patients and caregivers navigating the complex diagnosis, treatment and care landscape, self-organized communities can be a lifeline. Our experts at Avalere Health investigated how these groups can be best supported and when biopharmaceutical companies should partner – and should step back. Download the whitepaper now: https://bit.ly/3SRVGDA #AvalereHealth #RareDisease #PatientCommunities
Avalere Health | Putting the patient first: Moving from patient communities to patient co-creation in rare disease
avalerehealth.com
To view or add a comment, sign in
-
There are over 10,000 rare diseases impacting small patient populations, but 95% of these lack any FDA-approved treatment, says the National Organization for Rare Disorders. For patients and caregivers navigating the complex diagnosis, treatment and care landscape, self-organized communities can be a lifeline. Our experts at Avalere Health investigated how these groups can be best supported and when biopharmaceutical companies should partner – and should step back. Download the whitepaper now: https://bit.ly/3SRVGDA #AvalereHealth #RareDisease #PatientCommunities
Avalere Health | Putting the patient first: Moving from patient communities to patient co-creation in rare disease
avalerehealth.com
To view or add a comment, sign in
-
There are over 10,000 rare diseases impacting small patient populations, but 95% of these lack any FDA-approved treatment, says the National Organization for Rare Disorders. For patients and caregivers navigating the complex diagnosis, treatment and care landscape, self-organized communities can be a lifeline. Our experts at Avalere Health investigated how these groups can be best supported and when biopharmaceutical companies should partner – and should step back. Download the whitepaper now: https://bit.ly/3SRVGDA #AvalereHealth #RareDisease #PatientCommunities
Avalere Health | Putting the patient first: Moving from patient communities to patient co-creation in rare disease
avalerehealth.com
To view or add a comment, sign in
-
What is Wainua? Wainua (eplontersen) is used to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN or ATTRv-PN), which is a rare, progressive disease that can be fatal if not treated. Amyloidosis is a disease caused by a buildup of abnormal proteins called amyloid. Wainua is from a class of medications called LICA (ligand-conjugated antisense oligonucleotide). Wainua works by decreasing the amount of TTR protein that is made, which slows disease progression and improves neuropathy and the patient's quality of life. Wainua is given as a monthly self-administered subcutaneous injection, using an autoinjector. Wainua received FDA approval on December 21, 2023, after positive results from the phase III clinical trial NEURO-TTRansform (NCT04136184).
To view or add a comment, sign in
-
Below are some key details regarding the Phase 3 Study conducted by AstraZeneca and Amgen for severe uncontrolled asthma. This study, conducted across multiple centers, employs a randomized, double-blind, placebo-controlled, parallel-group design to evaluate the effectiveness and safety of tezepelumab in both adults and adolescents. Let’s explore the clinical results and observe how tezepelumab compares to the standard of care for patients. #ClinicalResearch #Astrazeneca #tezepelumabtrials #Asthma #ClinicalTrials #ResearchUpdate
To view or add a comment, sign in
-
Any time a promising new therapy hits the market for patients, we’re cheering here at DKP! Up until now, there has been little hope, outside of losing weight or adopting lifestyle changes, for the estimated 5% of U.S. adults suffering from non-alcoholic steatohepatitis (NASH), an advance type of liver disease. But this month, Madrigal Pharmaceuticals received FDA approval for Rezdiffra (resmetiron), the first and only FDA-approved treatment for adults with NASH (also sometimes called MASH) with moderate to severe liver fibrosis. Participants in the Phase 3 clinical trial experienced NASH resolution and no worsening of liver scarring. Helping manufacturers navigate the market for novel therapies is one of our sweet spots at DKP, so we are always excited when we hear about breakthroughs like this one for patients. We’re hopeful this represents just one of many new treatments gaining FDA approval in 2024. #fda #noveltherapy #newtreatment #healthcare24 #healthcare #healthcare2024 #patientaccess #marketaccess #mash #nash #liverdisease #nafld #fattyliver
To view or add a comment, sign in
-
Real Stories, Remarkable Results 📣 Hear how practices like yours are thriving with our seca and inHealth Lifestyle Therapeutics partnership. Their stories are just the beginning. Ready to write your own? Start with us. #secaInHealth #SuccessStories https://hubs.li/Q02h4tkl0
To view or add a comment, sign in
11,045 followers